|
|
|
Volumn 3, Issue 2, 2001, Pages 198-203
|
|
Technology evaluation: C242-DM1, ImmunoGen Inc
a
a
NONE
(Australia)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIBODY CONJUGATE;
ANTINEOPLASTIC AGENT;
BMS 182248;
COLCHICINE;
DACTINOMYCIN;
DAUNORUBICIN;
DOXORUBICIN;
DRUG ANALOG;
EP 00425235;
FLUOROURACIL;
FOLINIC ACID;
IMMUNOTOXIN;
IRINOTECAN;
JP 53124692;
MAYTANSINE;
METHOTREXATE;
MITOMYCIN;
MONOCLONAL ANTIBODY;
MONOCLONAL ANTIBODY C242;
MONOCLONAL ANTIBODY J591;
SB 408075;
THIOL GROUP;
TRIACYLGLYCEROL LIPASE;
UNCLASSIFIED DRUG;
VINBLASTINE;
VINCA ALKALOID;
ANIMAL CELL;
ANIMAL EXPERIMENT;
ANTIGEN SPECIFICITY;
ARTICLE;
COLON TUMOR;
CONTROLLED STUDY;
CYTOTOXICITY;
DRUG APPROVAL;
DRUG CONJUGATION;
DRUG INDUSTRY;
DRUG MECHANISM;
DRUG SCREENING;
EVALUATION;
HUMAN;
HUMAN CELL;
IN VITRO STUDY;
IN VIVO STUDY;
LUNG NON SMALL CELL CANCER;
MOUSE;
NAUSEA;
NONHUMAN;
PANCREAS CANCER;
PATENT;
TECHNOLOGY;
TOXICITY;
TUMOR REGRESSION;
VOMITING;
ANIMALS;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS, PHYTOGENIC;
CLINICAL TRIALS, PHASE I;
COLONIC NEOPLASMS;
HUMANS;
IMMUNOTOXINS;
MAYTANSINE;
MOLECULAR STRUCTURE;
STRUCTURE-ACTIVITY RELATIONSHIP;
ANIMALIA;
VINCA;
|
|
EID: 0035039414
PISSN: 14648431
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (23)
|
|
References (21)
|
